News and Trends 2 Aug 2022 Cellectis gets green light for non-Hodgkin lymphoma trial French-headquartered gene-editing biotech company Cellectis says the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The company plans to begin enrolling patients in the NatHaLi-01 study in the second half […] August 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 SNIPR Biome announces new patent granted for applications targeting E. coli infections SNIPR Biome has today (August 2) announced that it has been granted a patent for medical applications supporting the company’s lead program – a bacteriophage cocktail targeting E.coli infections. Granted by the US Patent and Trademark Office (USPTO), the patent adds to its intellectual property portfolio that contains more than 20 granted patents in the […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 FDA puts clinical hold on Beam Theraputics’ cancer therapy Beam Therapeutics Inc., a U.S. biotech company developing precision genetic medicines through base editing, says the company was informed via email last week that the U.S. Food and Drug Administration (FDA) has placed a hold on the BEAM-201 Investigational New Drug (IND) application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic […] August 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Ipsen and Marengo Therapeutics partner to push immuno-oncology candidates into the clinic Ipsen and Marengo Therapeutics, Inc. have announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. Ipsen also announced it is exercising its option to acquire exclusive worldwide rights to an investigational ERK (extracellular signal-regulated kinase) inhibitor, discovered by AGV Discovery. Ipsen and Marengo Therapeutics details The collaboration between […] August 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Immutep reports positive data from cancer study Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease, has announced new interim data from second-line NSCLC (non-small cell lung cancer) patients (Part B) in its phase 2 TACTI-002 trial. The data was presented at the IASLC 2022 World Conference of Lung Cancer (WCLC 2022) in Vienna, Austria, and […] August 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Clinical hold on trial for colorectal cancer drug lifted by FDA A clinical hold has been lifted by the US Food and Drug Administration (FDA) on a trial for a treatment for colorectal cancer after changes were made by the company responsible. Belgium-based Celyad Oncology SA is a clinical biotech company focused on finding and developing chimeric antigen receptor T cell (CAR T) therapies for cancer. […] August 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 29 Jul 2022 Cancer patients enrolled on study to predict immunotherapy response An observational study has started enrolling patients with advanced/metastatic non-small cell lung cancer (NSCLC). Florida-based Nilogen Oncosystems made the announcement today (July 29) that those who are receiving immune checkpoint inhibitors in the standard of care will be registered for the study. Using advanced artificial intelligence and machine learning algorithms to discover biomarker signatures as […] July 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2022 VerImmune raises $2.5M to develop virus-inspired particle immunotherapies VerImmune, Inc., a U.S. biotech company developing new therapeutic modalities that aim to redirect the body’s pre-existing immunity toward cancer, has obtained $2.5 million in seed funding. The round was led by SeedFolio, a seed series venture capital firm. The round also included participation from U.S. and global investment venture firms such as Ulu Ventures, […] July 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2022 Biotech startup Novasenta raises $40M to advance novel cancer therapeutics Novasenta Inc., a U.S. startup biotech company focused on the discovery and validation of novel targets to develop cancer therapies, has completed $40 million in Series A financing. The round was led by UPMC Enterprises. The funding will allow Novasenta to advance its pipeline of antibody-based therapeutics and expand its computational platforms for target discovery, […] July 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2022 Commercial personalized cancer cell profile developed in Taiwan Patients with stage 2 solid tumors could benefit from the world’s first commercial personalized cancer cell profiling, developed in Taiwan. Taipei-based CancerFree Biotech Ltd has developed the technology that will help stage 2 patients and above by shortening the selection process. The technology will be showcasing at US Bio 2022. This is the world’s first […] July 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 AGC Biologics announces gene therapy partnership with Altheia Science A new development partnership between gene therapy company Altheia Sciences, which pioneers cell and gene treatments, and AGC Biologics, will look at strategies to treat autoimmune disease and cancer. Specifically, the partnership will help advance development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing. PD-L1 […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Step Pharma moves into oncology clinical trials Step Pharma, which works on CTPS1 inhibition for the targeted treatment of cancer, has announced its lead asset STP938 has cleared both an Investigational New Drug (IND) application by the Food and Drug Administration (FDA), and a clinical trial application (CTA) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This means Step Pharma […] July 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email